Guido Boabaid May, Bruna Raquel de Souza, Bárbara Yasmin Gueuvoghlanian-Silva, Esther Camilo Dos Reis, Sofia Rech Mostardeiro, Paula Pedrassani Boabaid May, Elvis Cueva Mateo, Giovanna Grunewald Vietta, Giovana Weber Hoss
{"title":"巴西精神病患者药物基因等位基因和表型频率的分布。","authors":"Guido Boabaid May, Bruna Raquel de Souza, Bárbara Yasmin Gueuvoghlanian-Silva, Esther Camilo Dos Reis, Sofia Rech Mostardeiro, Paula Pedrassani Boabaid May, Elvis Cueva Mateo, Giovanna Grunewald Vietta, Giovana Weber Hoss","doi":"10.2217/pgs-2023-0075","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> This work was designed to identify the pharmacogenetic profile of Brazilian psychiatric patients receiving psychoactive drug treatment according to ethnicity. <b>Methods:</b> Based on the GnTech<sup>®</sup> database, this cross-sectional study analyzed data from self-reported sociodemographic and genetic results from the next-generation sequencing panel composed of 26 pharmacogenes from 359 psychotropic drug users. <b>Results:</b> Variant frequencies of multiple pharmacogenes presented differences between ethnicities (<i>CYP3A5</i>, <i>CYP2D6</i>, <i>CYP1A2</i>, <i>CYP2B6</i>, <i>CYP3A4</i>, <i>UGT1A4</i>, <i>UGT2B15</i>, <i>ABCB1 rs1045642</i>, <i>ADRA2A rs1800544</i>, <i>COMT rs4680</i>, <i>GRIK4 rs1954787</i>, <i>GSK3B rs334558</i>, <i>GSK3B rs6438552</i>, <i>HTR1A rs6295</i>, <i>HTR2A rs7997012</i>, <i>HTR2C rs1414334</i>, <i>MTHFR rs1801131</i>, <i>OPRM1 rs1799971</i> and <i>5-HTTLPR</i>), endorsing the necessity of individual-level analyses in drug treatment. <b>Conclusion:</b> A discussion of pharmacogenomic test implementation in psychiatric clinical practice is needed to improve treatment choices, especially in Brazil, a multiethnic country.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"747-760"},"PeriodicalIF":1.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Distribution of pharmacogene allele and phenotype frequencies in Brazilian psychiatric patients.\",\"authors\":\"Guido Boabaid May, Bruna Raquel de Souza, Bárbara Yasmin Gueuvoghlanian-Silva, Esther Camilo Dos Reis, Sofia Rech Mostardeiro, Paula Pedrassani Boabaid May, Elvis Cueva Mateo, Giovanna Grunewald Vietta, Giovana Weber Hoss\",\"doi\":\"10.2217/pgs-2023-0075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose:</b> This work was designed to identify the pharmacogenetic profile of Brazilian psychiatric patients receiving psychoactive drug treatment according to ethnicity. <b>Methods:</b> Based on the GnTech<sup>®</sup> database, this cross-sectional study analyzed data from self-reported sociodemographic and genetic results from the next-generation sequencing panel composed of 26 pharmacogenes from 359 psychotropic drug users. <b>Results:</b> Variant frequencies of multiple pharmacogenes presented differences between ethnicities (<i>CYP3A5</i>, <i>CYP2D6</i>, <i>CYP1A2</i>, <i>CYP2B6</i>, <i>CYP3A4</i>, <i>UGT1A4</i>, <i>UGT2B15</i>, <i>ABCB1 rs1045642</i>, <i>ADRA2A rs1800544</i>, <i>COMT rs4680</i>, <i>GRIK4 rs1954787</i>, <i>GSK3B rs334558</i>, <i>GSK3B rs6438552</i>, <i>HTR1A rs6295</i>, <i>HTR2A rs7997012</i>, <i>HTR2C rs1414334</i>, <i>MTHFR rs1801131</i>, <i>OPRM1 rs1799971</i> and <i>5-HTTLPR</i>), endorsing the necessity of individual-level analyses in drug treatment. <b>Conclusion:</b> A discussion of pharmacogenomic test implementation in psychiatric clinical practice is needed to improve treatment choices, especially in Brazil, a multiethnic country.</p>\",\"PeriodicalId\":20018,\"journal\":{\"name\":\"Pharmacogenomics\",\"volume\":\" \",\"pages\":\"747-760\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2023-0075\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0075","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Distribution of pharmacogene allele and phenotype frequencies in Brazilian psychiatric patients.
Purpose: This work was designed to identify the pharmacogenetic profile of Brazilian psychiatric patients receiving psychoactive drug treatment according to ethnicity. Methods: Based on the GnTech® database, this cross-sectional study analyzed data from self-reported sociodemographic and genetic results from the next-generation sequencing panel composed of 26 pharmacogenes from 359 psychotropic drug users. Results: Variant frequencies of multiple pharmacogenes presented differences between ethnicities (CYP3A5, CYP2D6, CYP1A2, CYP2B6, CYP3A4, UGT1A4, UGT2B15, ABCB1 rs1045642, ADRA2A rs1800544, COMT rs4680, GRIK4 rs1954787, GSK3B rs334558, GSK3B rs6438552, HTR1A rs6295, HTR2A rs7997012, HTR2C rs1414334, MTHFR rs1801131, OPRM1 rs1799971 and 5-HTTLPR), endorsing the necessity of individual-level analyses in drug treatment. Conclusion: A discussion of pharmacogenomic test implementation in psychiatric clinical practice is needed to improve treatment choices, especially in Brazil, a multiethnic country.
期刊介绍:
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.